Drug Eruptions Treatment Market Snapshot (2023 to 2033)
The global drug eruptions treatment market is expected to be worth US$ 3.89 Billion in the fiscal year 2023, which rose up from US$ 3.66 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 6.2% CAGR, reaching a value of US$ 7.1 Billion by the end of 2033.
A drug eruption is an unpleasant cutaneous response to a medication. Many medicines, including antimicrobials, NSAIDs, anticonvulsants, sulfa drugs, chemotherapeutic agents, and psychiatric meds, can induce adverse effects. Drug eruption treatment can mimic a range of different skin disorders and should therefore be evaluated in any patient who is taking drugs or has switched medications. Drug eruptions treatment often appears after 2 weeks of starting a new drug or even within days if re-exposure to a specific drug. Scratching is the most prevalent symptom.
Drug eruption treatment occurs in about 2-5% of hospitalized patients and more than 1% of outpatients. Adverse medication responses are more common in women, the elderly, and individuals with impaired immune systems.
The best way to cure a drug rash is to discontinue the medicine that is triggering it. After quitting a medication, it may require 5-10 days for the skin to heal and up to 3 weeks for the rashes to entirely resolve. Oral antihistamine tablets such as hydroxyzine, diphenhydramine, loratadine, fexofenadine, cetirizine, or desloratadine for irritation; topical corticosteroids (cortisone) lotions or creams for red, inflamed skin; and topical antimicrobial ointments for open sores are other options.
Attributes
Details
Expected Market Value (2023)
US$ 3.89 Billion
Projected Forecast Value (2033)
US$ 7.1 Billion
Global Growth Rate (2023 to 2033)
6.2%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 To 2022 Drug eruptions treatment Market Demand Analysis Vs. Forecast 2023 To 2033
The global drug eruption treatment market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. In most cases, drug eruptions treatment is identified clinically. Skin tests, for example, are performed in laboratories due to their great specificity. Treatment is often beneficial and includes discontinuation of the incorrect drug, indicated treatment, and patient education. For example, people who are allergic to penicillin are recommended to avoid all carbapenems as well as cephalosporins for their own safety. Such factors have been a major driver of this market for drug eruptions treatment.
The global drug eruptions treatment market is being driven by the introduction of innovative treatment approaches, increased knowledge of different drug allergies, and a growth in demand in emerging economies. The development of new medications and intensive continuing research for the prevention of any sort of drug allergy are important to market drivers. The global market for drug eruption treatment is expanding at a modest rate, which is projected to continue over the forecast period.
Such factors are expected to boost the global sales of drug eruptions treatment solutions. As a result, the global drug eruptions treatment market is expected to forecast a CAGR of over 6% from 2023 to 2033.
Prominent Growth Drivers Influencing drug eruptions treatment market
Various kinds of allergies to different drug types boost the demand
Both over-the-counter and prescription medications have the potential to be the problem. Antibiotics as well as other antimicrobial medications, sulfa medications, nonsteroidal anti-inflammatory medicines (NSAIDs), chemotherapeutic agents, anticonvulsants, biopharmaceuticals, and psychiatric medications are a few examples of common medications that can result in drug eruptions treatment. Examples of common reactions include photodermatitis brought on by topical NSAIDs (like piroxicam) or antibiotics (like minocycline), fixed drug eruptions treatment brought on by acetaminophen or NSAIDs (like Ibuprofen), and the rash that develops after ampicillin in instances of mononucleosis.
The rate of drug eruption treatment associated with several medications is thought to be fewer than 3 per 100 people exposed. Digoxin, aluminum hydroxide, vitamin supplements, bisacodyl, acetaminophen, aspirin, prednisone, thiamine, atropine, hydrochlorothiazide, codeine, morphine, warfarin, insulin, and spironolactone are a few of these. Such factors are sure to propel the market for drug eruptions treatment during the forecast period.
Several treatments for drug eruptions treatment to accelerate the growth
Drug eruptions treatment is being treated with a variety of medications. Desensitization, for instance, is occasionally used to treat drug eruptions treatment, especially when testing is not possible or available. As long as one keeps taking the medication, this method aims to temporarily enable the body to tolerate allergens.
For instance, during penicillin desensitization, progressively greater doses of penicillin are given at intervals until the immune system becomes used to the medication. Such developments are expected to accelerate the demand for drug eruption treatment during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
What Could Possibly Hinder Drug eruptions treatment Market Demand?
High costs and increasing pharmacovigilance impede the global market
During the review period, one of the biggest obstacles facing the worldwide market for drug eruptions treatment may be the high cost linked with them. Additionally, the advancement in drug eruptions treatment calls for highly qualified personnel, which might be one of the biggest obstacles for the global market.
Increasing pharmacovigilance at the same time can help to lessen drug side effects and, as a result, stop any potential eruptions caused by various medications. Thus, such factors can impede the growth of this market and hence curtail the demand for the treatment of drug eruptions treatment.
Region-wise Analysis
What is the outlook of the North American drug eruptions treatment market?
Rising technological advancements and skin rashes boost the regional demand
North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for drug eruption treatment, with a dominant 7.3% CAGR from 2023 to 2033.
This fast CAGR can be attributed to the increasing number of skin allergy sufferers in the United States of America, improved healthcare facilities, increased research and development in this domain, and cutting-edge technologies. Black Americans suffer mostly from various skin rashes and eruptions due to the various drugs, which lead to eczema and skin inflammation along with hay fever.
In the United States of America, a survey from 2021 found that among people who reported drug eruptions treatment, penicillin and related medicines accounted for 18% of cases. In addition, one in ten persons had an allergy to sulfonamide-containing antibiotics. Hence, there would be a lot of scopes for North American manufacturers to develop in this market during the forecast period.
What can be expected from the European market for drug eruptions treatment?
Increasing treatment options and innovations to propel the sales
During the forecast period, the European market for drug eruptions treatment is expected to garner a steady CAGR of 6.2%. But at the time, the European market for the management of drug eruptions treatment is expected to witness this market gain 27% in 2023.
Drug allergies affect 1% to 2% of hospital admissions and 3% to 5% of outpatients in the United Kingdom, however, it is unknown how common they are in the general population, including children and adults. Hence, the increasing incidence of drug reaction cases has made the European market an attraction for global manufacturers. The presence of the key players in this market has accelerated the revenues for the European market for drug eruptions treatment. Such developments are expected to accelerate the growth in the market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which drug type segment is expected to gain traction from 2023 to 2033?
The antihistamines segment will gain the dominant market share
Over the course of the forecast period, the antihistamine segment by product type is anticipated to occupy a significant share of the global drug eruptions treatment market. In 2023, this category is anticipated to dominate with a 41% revenue share.
Antihistamines may cause unforeseen type B adverse drug events, irrespective of the mechanism, thus it's critical to pay attention to the patient's condition in order to spot such bad reactions. Antihistamines are crucial medications used to treat urticaria and anaphylaxis, but it's vital to remember that antihistamines do have certain risks associated with their usage.
Also, antihistamines can cause bigger lesions on the epidermis, which can further lead to serious conditions. Such factors are expected to accelerate the growth prospects for drug eruptions treatment from 2023 to 2033.
Which route of administration segment is expected to gain traction from 2023 to 2033?
The intravenous segment will demand during the forecast period.
According to the research by Future Market Insights, the intravenous segments will gain popularity during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.
During a case of drug eruptions treatment, most of the time, the symptoms cannot be barred by the oral drugs solely. In such a case, the drug needs to be injected directly into the bloodstream so that they start working quickly. With the IV route of administration, the patients get faster relief from the various allergic reactions within their bodies. These benefits are expected to people the growth of this segment from 2023 to 2033.
Start-up Scenario
The new companies in this market are aimed at developing novel solutions for various kinds of drug eruptions treatment and allergies by curing the symptoms first. Some of the companies are:
Bioherent was created in 2021 to further the development of its laboratory prototype, which employs ultra-sensitive photonic biosensors to identify medication allergies, including beta-lactam antibiotics. One significant advantage of their approach was that, unlike previous integrated photonic biosensor devices, it did not need demanding components, making it relatively inexpensive to make and simple to deploy.
Using data and clinical research, Nectar creates a complete, vertically integrated allergy healthcare platform. The Nectar platform will employ data and clinical studies to provide individualized allergy care that will treat the underlying cause of allergies and provide long-term relief. Nectar's distinct strategy will give long-needed ease to clients by effortlessly transitioning between virtual treatment and physical clinics for complete allergy care addressing environmental, pet, eczema, drug allergies, and asthma.
Competitive Landscape
Some of the prominent players in the global market for drug eruptions treatment are:
Anuh Pharma Ltd.
Avik Pharma
Pfizer CentreOne
Hovione
Bausch Health Companies Inc.
APOTEX
Astellas Pharma, Inc.
Sanofi
Novartis AG
SBH Sciences
Some of the prominent developments of the key players in the market are:
Novartis announced in 2021 that the FDA has given ligelizumab (QGE031) the designation of 'Breakthrough Therapy' for the treatment of chronic spontaneous urticaria (CSU), commonly known as chronic idiopathic urticaria (CIU), in individuals who had an unsatisfactory reaction to H1-antihistamine therapy. Ligelizumab (QGE031) is a monoclonal anti-immunoglobulin E (IgE) antibody of the next generation. Ligelizumab is considered to act by inhibiting the IgE/FcRI pathway, which is known to be the main driver of the inflammation reaction in CSU. Ligelizumab against omalizumab is now being studied in Phase III clinical trial programs such as PEARL 1 and PEARL 2. (NCT03580369 and NCT03580356). The clinical studies have enrolled over 2,000 patients from 48 countries worldwide.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 6.2% from 2023 to 2033
Market value in 2023
US$ 3.89 Billion
Market value in 2033
US$ 7.1 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
USD Billion for Value
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug class
Route of Administration
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Key Countries Profiled
United States of America
Canada
Mexico
Brazil
Rest of Latin America
Germany
Italy
France
United Kingdom
Spain
Rest of Europe
Japan
Singapore
South Korea
Thailand
Indonesia
China
Australia
New Zealand
Japan
GCC Countries
South Africa
Israel
Middle East and Africa
Key Companies Profiled
Anuh Pharma Ltd.
Avik Pharma
Pfizer CentreOne
Hovione
Bausch Health Companies Inc.
APOTEX
Astellas Pharma, Inc.
Sanofi
Novartis AG
SBH Sciences
Customisation Scope
Available on Request
Frequently Asked Questions
What is the Growth Potential of the Market?
The market is forecast to register a CAGR of 6.2% through 2033.
What is the Projected Size of the Market by 2033?
The market is valued to reach US$ 7.1 Billion by 2033.
What Historical Changes Did the Market Undergo?
The global market advanced at a 5.1% HCAGR from 2018 to 2022.
Which Section May Become Vital Based on Drug Type?
The antihistamines sector is anticipated to grasp a sizable market share of 41%.
What Route of Administration Segment Will Capture a Large Share of the Market?
A sizeable 25% share pertains to the intravenous category.
What is the CAGR of the Europe Market?
The European market to garner a steady CAGR of 6.2%.
Table of Content
1. Executive Summary | Drug Eruptions Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Corticosteroids
5.3.2. Immunosuppressant Drugs
5.3.3. Anti-cytokines
5.3.4. Hemorrheologic Agents
5.3.5. Antihistamines
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Intravenous
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Online Pharmacies
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Route of Administration
14.20.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Anuh Pharma Ltd.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Avik Pharma
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Pfizer CentreOne
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Hovione
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Bausch Health Companies Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. APOTEX
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Astellas Pharma, Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Sanofi
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Novartis AG
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. SBH Sciences
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
